DK0640689T3 - p4-homodimer af interleukin-12. - Google Patents

p4-homodimer af interleukin-12.

Info

Publication number
DK0640689T3
DK0640689T3 DK94109773T DK94109773T DK0640689T3 DK 0640689 T3 DK0640689 T3 DK 0640689T3 DK 94109773 T DK94109773 T DK 94109773T DK 94109773 T DK94109773 T DK 94109773T DK 0640689 T3 DK0640689 T3 DK 0640689T3
Authority
DK
Denmark
Prior art keywords
interleukin
homodimer
kda
subunits
subunit
Prior art date
Application number
DK94109773T
Other languages
English (en)
Inventor
Maurice Kent Gately
John Hakimi
Ping Ling
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0640689T3 publication Critical patent/DK0640689T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Secondary Cells (AREA)
DK94109773T 1993-07-02 1994-06-24 p4-homodimer af interleukin-12. DK0640689T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8783293A 1993-07-02 1993-07-02

Publications (1)

Publication Number Publication Date
DK0640689T3 true DK0640689T3 (da) 2003-02-24

Family

ID=22207513

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94109773T DK0640689T3 (da) 1993-07-02 1994-06-24 p4-homodimer af interleukin-12.

Country Status (13)

Country Link
US (1) US5650492A (da)
EP (1) EP0640689B1 (da)
JP (1) JP3546076B2 (da)
AT (1) ATE226215T1 (da)
AU (1) AU675532B2 (da)
CA (1) CA2125763C (da)
DE (1) DE69431545T2 (da)
DK (1) DK0640689T3 (da)
ES (1) ES2184748T3 (da)
NZ (1) NZ260843A (da)
PT (1) PT640689E (da)
RU (1) RU2135584C1 (da)
ZA (1) ZA944567B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683046B1 (en) * 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
EP0820299B1 (en) * 1995-02-06 2002-04-24 Genetics Institute, Inc. Formulations for il-12
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
WO1997020062A1 (en) * 1995-12-01 1997-06-05 University Of Massachusetts Il-12 p40 subunit fusion polypeptides and uses thereof
AU702379B2 (en) 1996-06-04 1999-02-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Novel feline cytokine protein
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
EP0919241B1 (en) * 1997-05-16 2004-08-04 Toray Industries, Inc. Therapeutic agent, treatment method, prophylactic agent, and prophylactic method for canine and feline immunological diseases
EP1037927B1 (en) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
ATE357459T1 (de) * 1998-01-23 2007-04-15 Hoffmann La Roche Antikörper gegen mensliches il-12
US7026456B1 (en) * 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
CA2328076C (en) * 1998-04-15 2009-10-06 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE19919148A1 (de) * 1999-04-27 2000-11-16 Wieser Raimund J Von Interleukin 12 abgeleitete Peptid-Homodimere und Peptid-Heterodimere
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP1905832A3 (en) 1999-09-09 2009-09-09 Schering Corporation Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
DE60129695T2 (de) * 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
CN1330664C (zh) * 2001-03-07 2007-08-08 默克专利有限公司 用于含杂合同种型抗体部分的蛋白质的表达技术
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
MXPA04005266A (es) * 2001-12-04 2004-10-11 Merck Patent Gmbh Inmunocitocinas con selectividad modulada.
US7169904B2 (en) * 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
CA2536819A1 (en) * 2003-08-26 2005-03-03 The Council Of The Queensland Institute Of Medical Research Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium spp
BRPI0410805A (pt) * 2003-09-09 2006-06-27 Fumapharm Ag uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma
CA2552590A1 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
ES2384055T3 (es) 2005-12-30 2012-06-28 Merck Patent Gmbh Variantes de la interleucina-12p40 con estabilidad mejorada
CN104524567A (zh) * 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
EP3135282A1 (en) * 2007-02-08 2017-03-01 Biogen MA Inc. Neuroprotection in demyelinating diseases
WO2008121301A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human il-12 antibodies
KR20100126515A (ko) * 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
US20100172862A1 (en) * 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
WO2011032148A1 (en) * 2009-09-14 2011-03-17 Abbott Laboratories Methods for treating psoriasis
NO2709651T3 (da) * 2011-05-19 2018-03-03
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
HUE040044T2 (hu) 2013-03-14 2019-02-28 Alkermes Pharma Ireland Ltd Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US10765724B2 (en) 2016-03-29 2020-09-08 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (en) 2018-05-18 2022-02-23 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
DK3883606T5 (da) 2018-09-24 2024-01-02 Janssen Biotech Inc Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof
AU2019355971A1 (en) 2018-10-03 2021-05-06 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
AU2020358979A1 (en) 2019-10-03 2022-04-21 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
WO2024099445A1 (zh) * 2022-11-10 2024-05-16 康立泰生物医药(青岛)有限公司 聚乙二醇定点修饰异源聚体蛋白或多肽及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762623A1 (en) * 1988-01-22 2007-03-14 ZymoGenetics, Inc. Methods for producing biologically active peptide dimers
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
CA2051796A1 (en) * 1990-09-21 1992-03-22 Marvin L. Bayne Vascular endothelial cell growth factor ii
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12

Also Published As

Publication number Publication date
EP0640689A3 (en) 1995-06-28
AU6607294A (en) 1995-01-12
AU675532B2 (en) 1997-02-06
ATE226215T1 (de) 2002-11-15
ES2184748T3 (es) 2003-04-16
JP3546076B2 (ja) 2004-07-21
PT640689E (pt) 2003-03-31
RU2135584C1 (ru) 1999-08-27
JPH0753594A (ja) 1995-02-28
RU94022238A (ru) 1997-03-27
US5650492A (en) 1997-07-22
DE69431545T2 (de) 2003-06-26
CA2125763A1 (en) 1995-01-03
EP0640689A2 (en) 1995-03-01
EP0640689B1 (en) 2002-10-16
DE69431545D1 (de) 2002-11-21
NZ260843A (en) 1996-02-27
ZA944567B (en) 1995-12-27
CA2125763C (en) 2007-08-28

Similar Documents

Publication Publication Date Title
DK0640689T3 (da) p4-homodimer af interleukin-12.
DK0584125T3 (da) Afkortede former af hepatocyt vækstfaktor (HGF) receptor
EE9900492A (et) II tüüpi TGF-ß retseptori/immunoglobuliini konstantse piirkonna hübriidvalgud
DK1568772T3 (da) Varianter af humant væksthormon
NZ238403A (en) Heterocyclically-substituted phthalides and condensed analogues; herbicidal compositions thereof
ZA905150B (en) Substituted quinazolinones as angiotensin ii antagonists
DK1246846T3 (da) Oplöselig interleukin-20-receptor
MY123740A (en) Il-13 receptor polypeptide
ES2117623T3 (es) Receptor de la interleuquina-2 recombinante.
DE69536113D1 (de) Rezeptor für modifizierte Lipoprotein niedriges Molekulargewichtes
DK1908772T3 (da) Polypeptider og polynucleinsyrer af phorphorymonas gingivalis
IT1304499B1 (it) Procedimento per ridurre il peso molecolare di copolimeri eterpolimeri dell'etilene.
ES2152328T3 (es) Antagonistas del receptor del fibrinogeno.
DK271889D0 (da) Laegemiddel paa basis af en aryloxypropanolamin til selektiv antagonisering af 5-ht1-receptorer
DK0648762T3 (da) Bicykliske forbindelser som excitatoriske aminosyrereceptorantagonister
DE69004821D1 (de) Polyamidharz-Zusammensetzung.
MY124125A (en) Self-fusible insulated wire
FI921356A (fi) Somatostatinreceptor
ITTO971042A1 (it) Procedimento per l'accrescimento del peso molecolare di resine.
IL142464A0 (en) Non-desensitizing ampa-receptors